Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Marjaanai L"'
Autor:
Hervonen P, Joensuu H, Joensuu T, Ginman C, Claes G, Ray McDermott, Ray M, Harmenberg U, Ulrika H, Nyandoto P, Paul N, Luukkaala T, Tiina L, Hemminki A, Akseli H, Zaitsev I, Igor Z, Heikkinen M, Mirja H, Nilsson S, Sten N, Luukkaa M, Marjaanai L, Lehtinen I, Ilari L, Pl, Kellokumpu-Lehtinen, Kl, Pirkko-Liisa
Publikováno v:
Europe PubMed Central
Docetaxel administered every three weeks is the standard treatment for advanced hormone-refractory prostate cancer (HRPC). However, biweekly administration might be better tolerated due to the reduced peak drug concentrations. Therefore, we compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::a4cafd7553e717daf6ec3827684913c5
https://pubmed.ncbi.nlm.nih.gov/22399616
https://pubmed.ncbi.nlm.nih.gov/22399616
